These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27261335)

  • 1. RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy.
    Rengaswamy V; Zimmer D; Süss R; Rössler J
    J Control Release; 2016 Aug; 235():319-327. PubMed ID: 27261335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.
    Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM
    Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquisition of an oncogenic fusion protein serves as an initial driving mutation by inducing aneuploidy and overriding proliferative defects.
    Loupe JM; Miller PJ; Bonner BP; Maggi EC; Vijayaraghavan J; Zabaleta J; Taylor CM; Tsien F; Crabtree JS; Hollenbach AD
    Oncotarget; 2016 Sep; 7(39):62814-62835. PubMed ID: 27588498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis.
    Deel MD; Slemmons KK; Hinson AR; Genadry KC; Burgess BA; Crose LES; Kuprasertkul N; Oristian KM; Bentley RC; Linardic CM
    Clin Cancer Res; 2018 Jun; 24(11):2616-2630. PubMed ID: 29514840
    [No Abstract]   [Full Text] [Related]  

  • 5. Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma.
    Lacey A; Hedrick E; Cheng Y; Mohankumar K; Warren M; Safe S
    Mol Cancer Ther; 2018 Dec; 17(12):2756-2766. PubMed ID: 30190424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphingosine Induces Apoptosis and Down-regulation of
    Ahn EH; Lee MB; Seo DJ; Lee J; Kim Y; Gupta K
    Anticancer Res; 2018 Jan; 38(1):71-76. PubMed ID: 29277758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Alveolar rhabdomyosarcoma: Two fusion-negative cases lacking PAX3-FOXO1 and PAX7-FOXO1].
    Mestre-Alagarda C; Gómez-Mateo MC; Berenguer-Romero MD; Syonghyun NC; Nieto G; Navarro-Fos S
    Rev Esp Patol; 2022; 55(1):57-62. PubMed ID: 34980443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma.
    Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J
    Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAX3-FOXO1: Zooming in on an "undruggable" target.
    Wachtel M; Schäfer BW
    Semin Cancer Biol; 2018 Jun; 50():115-123. PubMed ID: 29146205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
    Ahn EH
    Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis.
    Oristian KM; Crose LES; Kuprasertkul N; Bentley RC; Lin YT; Williams N; Kirsch DG; Linardic CM
    Cancer Res; 2018 Oct; 78(19):5513-5520. PubMed ID: 30093562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of PAX3/7-FOXO1 fusion status in alveolar rhabdomyosarcoma: Systematic review and meta-analysis.
    Kubo T; Shimose S; Fujimori J; Furuta T; Ochi M
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):46-53. PubMed ID: 26008753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
    Ahn EH; Mercado GE; Laé M; Ladanyi M
    Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements.
    Vicente-García C; Villarejo-Balcells B; Irastorza-Azcárate I; Naranjo S; Acemel RD; Tena JJ; Rigby PWJ; Devos DP; Gómez-Skarmeta JL; Carvajal JJ
    Genome Biol; 2017 Jun; 18(1):106. PubMed ID: 28615069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.
    Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG
    J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma.
    Jothi M; Mal M; Keller C; Mal AK
    Mol Cancer Ther; 2013 Dec; 12(12):2663-74. PubMed ID: 24107448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors.
    Searcy MB; Larsen RK; Stevens BT; Zhang Y; Jin H; Drummond CJ; Langdon CG; Gadek KE; Vuong K; Reed KB; Garcia MR; Xu B; Kimbrough DW; Adkins GE; Djekidel N; Porter SN; Schreiner PA; Pruett-Miller SM; Abraham BJ; Rehg JE; Hatley ME
    Nat Commun; 2023 Nov; 14(1):7291. PubMed ID: 37968277
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Kendall GC; Watson S; Xu L; LaVigne CA; Murchison W; Rakheja D; Skapek SX; Tirode F; Delattre O; Amatruda JF
    Elife; 2018 Jun; 7():. PubMed ID: 29869612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HDAC3-SMARCA4-miR-27a axis promotes expression of the
    Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Ishikawa Y; Zientek K; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Rudek MA; Xu L; Anders NM; Pal R; Harrold AP; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Chatterjee B; Bächinger HP; Barr FG; Liddle J; Garcia BA; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
    Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
    Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
    Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.